Skeletal muscle channelopathies: New insights into the periodic paralyses and nondystrophic myotonias

Current Opinion in Neurology

Volumn 22, Issue 5, 2009, Pages 524-531

  Platt, Daniel ^a   Griggs, Robert ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

Channelopathies; Myotonia; Periodic paralysis; Ryanodine receptor

Indexed keywords

ACETAZOLAMIDE; CALCIUM CHANNEL; CARBAMAZEPINE; CHLORIDE CHANNEL; DICLOFENAMIDE; FLECAINIDE; MEXILETINE; PHENYTOIN; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; PROPAFENONE; SODIUM CHANNEL; TOCAINIDE;

ANDERSEN SYNDROME; CHANNEL GATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; EXERCISE; GENE MUTATION; GENETIC SCREENING; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE CHANNELOPATHY; MYOTONIA; NONDYSTROPHIC MYOTONIA; PATHOPHYSIOLOGY; PERIODIC PARALYSIS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RYANODINOPATHY; THOMSEN DISEASE;

CHANNELOPATHIES; HUMANS; ION CHANNELS; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; MYOPATHY, CENTRAL CORE; MYOTONIC DISORDERS; PARALYSES, FAMILIAL PERIODIC;

EID: 70349667578     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832efa8f     Document Type: Review

References (85)

1. Lehmann-Horn F, Rudel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol 1995; 8:402-410.
2. Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J Physiol 1971; 219:367-383.
3. Papponen H, Nissinen M, Kaisto T, et al. F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulumexport of the muscle-specific chloride channel CLC-1. Muscle Nerve 2008; 37:317-325.
4. Colding-Jorgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve 2005; 32:19-34.
5. Morales F,Cuenca P,del Valle G,et al.Clinicalandmoleculardiagnosisofa Costa Rican family with autosomal recessive myotonia congenita (Becker disease) carrying a new mutation in the CLCN1 gene. Rev Biol Trop 2008; 56:1-11.
6. Burgunder JM, Huifang S, Beguin P, et al. Novel chloride channel mutations leading to mild myotonia among Chinese. Neuromuscul Disord 2008; 18:633-640.
7. Trip J, Drost G, Verbove DJ, et al. In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with nondystrophic myotonia. Eur J Hum Genet 2008; 16:921-929.
8. Duffield M, Rychkov G, Bretag A, Roberts M. Involvement of helices at the dimer interface in ClC-1 common gating. J Gen Physiol 2003; 121:149-161.
9. Bernard G, Poulin C, Puymirat J, et al. Dosage effect of a dominant CLCN1 mutation: a novel syndrome. J Child Neurol 2008; 23:163-166.
10. Heatwole CR, Moxley RT 3rd. The nondystrophic myotonias. Neurotherapeutics 2007; 4:238-251.
11. Horlings CG, Drost G, Bloem BR, et al. Trunk sway analysis to quantify the warm-up phenomenon in myotonia congenita patients. J Neurol Neurosurg Psychiatry 2009; 80:207-212.
12. Fialho D, Kullmann DM, Hanna MG, Schorge S. Nongenomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita. Neuromuscul Disord 2008; 18:869-872.
13. Gay S, Dupuis D, Faivre L, et al. Severe neonatal nondystrophic myotonia secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene. Am J Med Genet A 2008; 146:380-383.
14. Fournier E, Viala K, Gervais H, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol 2006; 60:356-365.
15. Kubota T, Kinoshita M, Sasaki R, et al. New mutation of the Na channel in the severe form of potassium-aggravated myotonia. Muscle Nerve 2009; 39:666-673.
16. Matthews E, Tan SV, Fialho D, et al. What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. Neurology 2008; 70:50-53.
17. Vicart S, Sternberg D, Fontaine B, Meola G. Human skeletal muscle sodium channelopathies. Neurol Sci 2005; 26:194-202.
18. Streib EW. Paramyotonia congenita. Semin Neurol 1991; 11:249-257.
19. Rudel R, Lehmann-Horn F. Paramyotonia, potassium-aggravated myotonias and periodic paralyses. 37th ENMC International Workshop, Naarden, The Netherlands, 8-10 December 1995. Neuromuscul Disord 1997; 7:127-132.
20. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci 2006; 29:387-415.
21. Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics 2007; 4:216-224.
22. Bradley WG, Taylor R, Rice DR, et al. Progressive myopathy in hyperkalemic periodic paralysis. Arch Neurol 1990; 47:1013-1017.
23. Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129 (Pt 1):8-17.
24. Meyers KR, Gilden DH, Rinaldi CF, Hansen JL. Periodic muscle weakness, normokalemia, and tubular aggregates. Neurology 1972; 22:269-279.
25. Poskanzer DC, Kerr DN. A third type of periodic paralysis, with normokalemia and favourable response to sodium chloride. Am J Med 1961; 31:328-342.
26. Chinnery PF, Walls TJ, Hanna MG, et al. Normokalemic periodic paralysis revisited: does it exist? Ann Neurol 2002; 52:251-252.
27. Plassart E, Reboul J, Rime CS, et al. Mutations in the muscle sodium channel gene (SCN4A) in 13 French families with hyperkalemic periodic paralysis and paramyotonia congenita: phenotype to genotype correlations and demonstration of the predominance of two mutations.Eur JHumGenet 1994; 2:110-124.
28. Vicart S, Sternberg D, Fournier E, et al. New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. Neurology 2004; 63:2120-2127.
29. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. A calcium channel mutation causing hypokalemic periodic paralysis. HumMolGenet 1994; 3:1415-1419.
30. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77:863-868.
31. Fontaine B, Fournier E, Sternberg D, et al. Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder. Neurotherapeutics 2007; 4:225-232.
32. Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001; 124 (Pt 6):1091-1099.
33. Jurkat-Rott K, Mitrovic N, Hang C, et al. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A 2000; 97:9549-9554.
34. Davies NP, Eunson LH, Samuel M, Hanna MG. Sodium channel gene mutations in hypokalemic periodic paralysis: an uncommon cause in the UK. Neurology 2001; 57:1323-1325.
35. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105:511-519.
36. Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 2007; 4:233-237.
37. Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002; 110:381-388.
38. Zhang L, Benson DW, Tristani-Firouzi M, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic TU- wave patterns predict the KCNJ2 genotype. Circulation 2005; 111:2720-2726.
39. Morita H, Zipes DP, Morita ST, Wu J. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res 2007; 75:510-518.
40. Jurkat-Rott K, Lerche H, Lehmann-Horn F. Skeletal muscle channelopathies. J Neurol 2002; 249:1493-1502.
41. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999; 79:1317-1372.
42. Jungbluth H. Central core disease. Orphanet J Rare Dis 2007; 2:25.
43. Treves S, Anderson AA, Ducreux S, et al. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul Disord 2005; 15:577-587.
44. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006; 33:715-731.
45. Mindell JA, Maduke M, Miller C, Grigorieff N. Projection structure of a ClCtype chloride channel at 6.5 A resolution. Nature 2001; 409:219-223.
46. Saviane C, Conti F, Pusch M. The muscle chloride channel ClC-1 has a double-barrelled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol 1999; 113:457-468.
47. Palade PT, Barchi RL. On the inhibition of muscle membrane chloride conductance by aromatic carboxylic acids. J Gen Physiol 1977; 69:879-896.
48. Wagner S, Deymeer F, Kurz LL, et al. The dominant chloride channel mutant G200R causing fluctuating myotonia: clinical findings, electrophysiology, and channel pathology. Muscle Nerve 1998; 21:1122-1128.
49. George AL Jr, Sloan-Brown K, Fenichel GM, et al. Nonsense and missense mutations of the muscle chloride channel gene in patients with myotonia congenita. Hum Mol Genet 1994; 3:2071-2072.
50. Heine R, George AL Jr, Pika U, et al. Proof of a nonfunctional muscle chloride channel in recessive myotonia congenita (Becker) by detection of a 4 base pair deletion. Hum Mol Genet 1994; 3:1123-1128.
51. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat 2002; 19:423-434.
52. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117:3952-3957.
53. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007; 28:334-341.
54. Petitprez S, Tiab L, Chen L, et al. A novel dominant mutation of the Nav1.4 alpha-subunit domain I leading to sodium channel myotonia. Neurology 2008; 71:1669-1675.
55. Webb J, Cannon SC. Cold-induced defects of sodium channel gating in atypical periodic paralysis plus myotonia. Neurology 2008; 70:755-761.
56. Carle T, Fournier E, Sternberg D, et al. Cold-induced disruption of Na+ channel slow inactivation underlies paralysis in highly thermosensitive paramyotonia J Physiol 2009; 587 (Pt 8):1705-1714.
57. Kuzmenkin A, Muncan V, Jurkat-Rott K, et al. Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II. Brain 2002; 125 (Pt 4):835-843.
58. Kuzmenkin A, Hang C, Kuzmenkina E, Jurkat-Rott K. Gating of the HypoPP-1 mutations: I. Mutant-specific effects and cooperativity. Pflugers Arch 2007; 454:495-505. (Pubitemid 46742439)
59. Carle T, Lhuillier L, Luce S, et al. Gating defects of a novel Na+ channel mutant causing hypokalemic periodic paralysis. Biochem Biophys Res Commun 2006; 348:653-661.
60. Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature 2007; 446:76-78.
61. Struyk AF, Cannon SC. A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore. J Gen Physiol 2007; 130:11-20.
62. Struyk AF, Markin VS, Francis D, Cannon SC. Gating pore currents in DIIS4 mutations of NaV1.4 associated with periodic paralysis: saturation of ion flux and implications for disease pathogenesis. J Gen Physiol 2008; 132:447-464.
63. Sokolov S, Scheuer T, Catterall WA. Depolarization-activated gating pore current conducted by mutant sodium channels in potassium-sensitive normokalemic periodic paralysis. Proc Natl Acad Sci U S A 2008; 105:19980-19985.
64. Chabrier S, Monnier N, Lunardi J. Early onset of hypokalaemic periodic paralysis caused by a novel mutation of the CACNA1S gene. J Med Genet 2008; 45:686-688.
65. Jurkat-Rott K, Weber MA, Fauler M, et al. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci U S A 2009; 106:4036-4041.
66. Jongsma HJ, Wilders R. Channelopathies: Kir2.1 mutations jeopardize many cell functions. Curr Biol 2001; 11:R747-R750.
67. Ballester LY, Vanoye CG, George AL Jr. Exaggerated Mg2+ inhibition of Kir2.1 as a consequence of reduced PIP2 sensitivity in Andersen syndrome. Channels (Austin) 2007; 1:209-217.
68. Tani Y, Miura D, Kurokawa J, et al. T75M-KCNJ2 mutation causing Andersen- Tawil syndrome enhances inward rectification by changing Mg2+ sensitivity. J Mol Cell Cardiol 2007; 43:187-196.
69. Decher N, Renigunta V, Zuzarte M, et al. Impaired interaction between the slide helix and the C-terminus of Kir2.1: a novel mechanism of Andersen syndrome. Cardiovasc Res 2007; 75:748-757.
70. Trip J, Drost G, Ginjaar I, et al. Redefining the clinical phenotypes of nondystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry 2009; 80:647-652.
71. Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004; 56:650-661.
72. Weber MA, Nielles-Vallespin S, Essig M, et al. Muscle Na+ channelopathies: MRI detects intracellular 23Na accumulation during episodic weakness. Neurology 2006; 67:1151-1158.
73. Weber MA, Nielles-Vallespin S, Huttner HB, et al. Evaluation of patients with paramyotonia at 23Na MR imaging during cold-induced weakness. Radiology 2006; 240:489-500.
74. Fialho D, Schorge S, Pucovska U, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain 2007; 130 (Pt 12):3265-3274.
75. Cleland JC, Griggs RC. Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics 2008; 5:607-612.
76. Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006;(1)(1):CD004762.
77. Tricarico D, Mele A, Conte Camerino D. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels. Neuromuscul Disord 2006; 16:39-45.
78. Camerino DC, Tricarico D, Desaphy JF. Ion channel pharmacology. Neurotherapeutics 2007; 4:184-198.
79. Tricarico D, Lovaglio S, Mele A, et al. Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats. Br J Pharmacol 2008; 154:183-190.
80. Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev 2008;(1)(1):CD005045.
81. Erdogan O, Aksoy A, Turgut N, et al. Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome. J Electrocardiol 2008; 41:325-328.
82. Sumitomo N, Shimizu W, Taniguchi K, Hiraoka M. Calcium channel blocker and adenosine triphosphate terminate bidirectional ventricular tachycardia in a patient with Andersen-Tawil syndrome. Heart Rhythm 2008; 5:498-499.
83. Fox DJ, Klein GJ, Hahn A, et al. Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome. Europace 2008; 10:1006-1008.
84. Pellizzon OA, Kalaizich L, Ptacek LJ, et al. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. J Cardiovasc Electrophysiol 2008; 19:95-97.
85. Bokenkamp R, Wilde AA, Schalij MJ, Blom NA. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. Heart Rhythm 2007; 4:508-511.